In this chapter Topol discusses the future of lab tests. It is a bit dated as he lauds Theranos prior to their implosion, so it is a kind of trip down memory lane.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.